NDAORALELIXIR
Approved
Jan 1965
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 5h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
MAXIBOLIN (ethylestrenol) is an oral anabolic steroid elixir originally approved by Merck & Co. in 1965 for select therapeutic indications. It functions as a synthetic androgenic compound with anabolic properties. The product is now in late-stage lifecycle with loss of exclusivity approaching.
LOE Approaching
Product is in late lifecycle with minimal commercial expansion opportunity; teams are likely focused on defending remaining market share rather than growth initiatives.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
MAXIBOLIN presents limited career advancement opportunities given its late-lifecycle status and minimal linked job openings. Roles on this product are primarily defensive, focused on compliance, supply chain management, and maintaining existing market position rather than innovation or expansion.
Brand ManagerProduct Manager
Worked on MAXIBOLIN at Merck & Co.? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.